Moderna’s Covid-19 vaccine development appears to be at its home stretch. Last week, the company said that it completed the enrollment process of 30,000 participants in its final-stage study, with initial data on the efficacy of the vaccine expected by late November. The company will apply…
Source: Forbes Markets
